Brexpiprazole

CHEMBL2105760 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

433.6 g/mol

LogP

4.7

Phase

4

An atypical antipsychotic used as an adjunct treatment for major depressive disorder and for schizophrenia, and also approved for agitation associated with Alzheimer's dementia. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonizes serotonin 5-HT2A receptors. It is taken once daily and generally has a favorable tolerability profile.

分子量

433.6000 g/mol

LogP

4.70

TPSA

73.10 Å²

リピンスキーの五則

適合

治療領域

Alzheimer's Disease Schizophrenia Generalized Anxiety Disorder Stroke Major Depressive Disorder

作用機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1

InChI

InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)

Molecular Formula

C25H27N3O2S

HBD / HBA

1 / 5

回転可能結合数

7

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An atypical antipsychotic used as an adjunct treatment for major depressive disorder and for schizophrenia, and also approved for agitation associated with Alzheimer's dementia. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonizes serotonin 5-HT2A receptors. It is taken once daily and generally has a favorable tolerability profile.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Brexpiprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105760. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11978813. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Brexpiprazole PillFYIで

構造

クイックデータ

分子式: C25H27N3O2S
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.